Merck’s Mevacor Returns For OTC Switch Consideration
This article was originally published in The Tan Sheet
Executive Summary
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug